216 related articles for article (PubMed ID: 18470919)
41. Surface-attached PEO in the form of activated Pluronic with immobilized factor H reduces both coagulation and complement activation in a whole-blood model.
Andersson J; Bexborn F; Klinth J; Nilsson B; Ekdahl KN
J Biomed Mater Res A; 2006 Jan; 76(1):25-34. PubMed ID: 16250010
[TBL] [Abstract][Full Text] [Related]
42. Reciprocal relationship between contact and complement system activation on artificial polymers exposed to whole human blood.
Huang S; Engberg AE; Jonsson N; Sandholm K; Nicholls IA; Mollnes TE; Fromell K; Nilsson B; Ekdahl KN
Biomaterials; 2016 Jan; 77():111-9. PubMed ID: 26584351
[TBL] [Abstract][Full Text] [Related]
43. Mechanism of complement activation during extracorporeal blood-biomaterial interaction: effects of heparin coated and uncoated surfaces.
Kopp R; Mottaghy K; Kirschfink M
ASAIO J; 2002; 48(6):598-605. PubMed ID: 12455769
[TBL] [Abstract][Full Text] [Related]
44. Covalent immobilization of hirudin improves the haemocompatibility of polylactide-polyglycolide in vitro.
Seifert B; Romaniuk P; Groth T
Biomaterials; 1997 Nov; 18(22):1495-502. PubMed ID: 9426179
[TBL] [Abstract][Full Text] [Related]
45. Influence of O(2)-carrying plasma hemoprotein "albumin-heme" on complement system and platelet activation in vitro and physiological responses to exchange transfusion.
Komatsu T; Huang Y; Wakamoto S; Abe H; Fujihara M; Azuma H; Ikeda H; Yamamoto H; Horinouchi H; Kobayashi K; Tsuchida E
J Biomed Mater Res A; 2007 Jun; 81(4):821-6. PubMed ID: 17236218
[TBL] [Abstract][Full Text] [Related]
46. Hemofiltration of recombinant hirudin by different hemodialyzer membranes: implications for clinical use.
Benz K; Nauck MA; Böhler J; Fischer KG
Clin J Am Soc Nephrol; 2007 May; 2(3):470-6. PubMed ID: 17699453
[TBL] [Abstract][Full Text] [Related]
47. Blood coagulation on biomaterials requires the combination of distinct activation processes.
Sperling C; Fischer M; Maitz MF; Werner C
Biomaterials; 2009 Sep; 30(27):4447-56. PubMed ID: 19535136
[TBL] [Abstract][Full Text] [Related]
48. In vitro evaluation of platelet reactivity toward annuloplasty devices treated with heparin coating: studies under flow conditions.
Tonda R; Galán AM; Pino M; Hernández MR; Ayats C; Pomar JL; Ordinas A; Escolar G
J Biomed Mater Res A; 2005 Oct; 75(1):192-8. PubMed ID: 16044416
[TBL] [Abstract][Full Text] [Related]
49. Exposure of blood to biomaterial surfaces liberates substances that activate polymorphonuclear granulocytes.
Karlsson C; Nygren H; Braide M
J Lab Clin Med; 1996 Nov; 128(5):496-505. PubMed ID: 8900293
[TBL] [Abstract][Full Text] [Related]
50. In vitro effect of hirudin on recalcification time.
Hirsh J; Spillert CR; Delle Donne EP; Lazaro EJ
J Natl Med Assoc; 1994 Aug; 86(8):627-8. PubMed ID: 7932843
[TBL] [Abstract][Full Text] [Related]
51. Assessment of blood interactions with the Therapore Apheresis System.
Pitt AM; O'Connor JL; Valeri CR; Castino F
Life Support Syst; 1987; 5(4):347-52. PubMed ID: 2963177
[TBL] [Abstract][Full Text] [Related]
52. Clinical and biomaterial evaluation of hyaluronan-based heparin-bonded extracorporeal circuits with reduced versus full systemic anticoagulation in reoperation for coronary revascularization.
Gunaydin S; Farsak B; McCusker K; Vijay V; Sari T; Onur MA; Gurpinar A; Zorlutuna Y
J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):135-42. PubMed ID: 19377380
[TBL] [Abstract][Full Text] [Related]
53. Melagatran prevents tissue factor expression in human platelet-monocyte heterotypic complexes.
Belliard A; Mauco G; Bonnet ML; Hauet T; Macchi L
Cell Mol Biol (Noisy-le-grand); 2008 Dec; 54 Suppl():OL1077-82. PubMed ID: 19149969
[TBL] [Abstract][Full Text] [Related]
54. The complement factor properdin induces formation of platelet-leukocyte aggregates via leukocyte activation.
Ruef J; Kuehnl P; Meinertz T; Merten M
Platelets; 2008 Aug; 19(5):359-64. PubMed ID: 18791942
[TBL] [Abstract][Full Text] [Related]
55. Anticoagulants Influence the Performance of In Vitro Assays Intended for Characterization of Nanotechnology-Based Formulations.
Cedrone E; Neun BW; Rodriguez J; Vermilya A; Clogston JD; McNeil SE; Barenholz Y; Szebeni J; Dobrovolskaia MA
Molecules; 2017 Dec; 23(1):. PubMed ID: 29267243
[TBL] [Abstract][Full Text] [Related]
56. Tubing loops as a model for cardiopulmonary bypass circuits: both the biomaterial and the blood-gas phase interfaces induce complement activation in an in vitro model.
Gong J; Larsson R; Ekdahl KN; Mollnes TE; Nilsson U; Nilsson B
J Clin Immunol; 1996 Jul; 16(4):222-9. PubMed ID: 8840224
[TBL] [Abstract][Full Text] [Related]
57. Heparin molecularly imprinted surfaces for the attenuation of complement activation in blood.
Rosengren-Holmberg JP; Andersson J; Smith JR; Alexander C; Alexander MR; Tovar G; Ekdahl KN; Nicholls IA
Biomater Sci; 2015 Aug; 3(8):1208-17. PubMed ID: 26222036
[TBL] [Abstract][Full Text] [Related]
58. Flow cytometric evaluation of platelet activation by ionic or nonionic contrast media and modulation by heparin and recombinant hirudin.
Koza MJ; Shankey TC; Walenga JM; Moncada R; Fareed J; Pifarre R
Invest Radiol; 1995 Feb; 30(2):90-7. PubMed ID: 7782193
[TBL] [Abstract][Full Text] [Related]
59. The effect of anticoagulants and the role of thrombin on neutrophil-endothelial cell interactions in septic shock.
Tsen A; Kirschenbaum LA; LaRow C; Khan R; Kurtz S; Bansal S; Astiz ME
Shock; 2009 Feb; 31(2):120-4. PubMed ID: 18636042
[TBL] [Abstract][Full Text] [Related]
60. In vitro studies on hirudin elimination by haemofiltration: comparison of three high-flux membranes.
Frank RD; Farber H; Lanzmich R; Floege J; Kierdorf HP
Nephrol Dial Transplant; 2002 Nov; 17(11):1957-63. PubMed ID: 12401853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
